Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
CDK2 degrader 1
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "CDK2 degrader 1" in MCE Product Catalog:
Cat. No.: HY-163814
CAS No.: 3036604-59-5
Target:
Research Areas:
CDK2 degrader 1 is a selective CDK2 molecular glue degrader. CDK2 degrader 1 binds to cereblon, induces ubiquitination of CDK2 and subsequent degradation via the proteasomal pathway. CDK2 degrader 1 is applicable for cancer-related research .
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand .
Cat. No.: HY-168057
CAS No.: 3024971-78-3
PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC50 of 100-500 nM .
Research Areas:
Thalidomide-C2-amido-C2-COOH contains a CRBN ligand and a linker for recruiting E3 ubiquitin ligases. Thalidomide-C2-amido-C2-COOH can be used to design and synthesize PROTAC CDK2/9 Degrader-1 (HY-130709). PROTAC CDK2/9 Degrader-1 is applicable to prostate cancer-related research .
Cat. No.: HY-179688
PROTAC CDK2/4 Degrader-1 is a PROTAC degrader of cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase 4 (CDK4). PROTAC CDK2/4 Degrader-1 induces degradation via the ubiquitin-proteasome pathway. PROTAC CDK2/4 Degrader-1 can be used in cancer research .
Cat. No.: HY-186132
CAS No.: 3030276-48-0
PROTAC CDK2-pRb degrader-1 is an orally active PROTAC-class degrader of CDK2. PROTAC CDK2-pRb degrader-1 effectively inhibits the phosphorylation of retinoblastoma protein (Rb) at serine residues 807/811 by inducing ubiquitination and proteasomal degradation of CDK2. PROTAC CDK2-pRb degrader-1 exhibits significant activity against human cells (with EC50 values of 12 nM and 125 nM, respectively). In xenograft models, PROTAC CDK2-pRb degrader-1 effectively inhibits tumor growth and induces tumor stasis, making it suitable for research related to CCNE1-amplified cancers (such as ovarian cancer, gastric cancer, and breast cancer) .
Cat. No.: HY-171826
CAS No.: 2541626-55-3
PROTAC CDK2/4/6 Degrader-1 is an orally active CDK2/CDK4/CDK6 PROTAC degrader. PROTAC CDK2/4/6 Degrader-1 is a prodrug derived from PROTAC CDK2/4/6 Degrader-2 via one-step reaction with chloromethyl pivalate. PROTAC CDK2/4/6 Degrader-1 can be used for malignant melanoma research .
Cat. No.: HY-161708
CAS No.: 3075001-08-7
PROTAC FLT3/CDKs degrader-1 is a PROTAC degrader targeting CDKs and FLT3. PROTAC FLT3/CDKs degrader-1 degrades CDK2, CDK4, CDK6, CDK9 and FLT3 proteins via a ubiquitin-proteasome-dependent bivalent mechanism, with a DC50 of 18.73 nM against CDK2. PROTAC FLT3/CDKs degrader-1 promotes myeloid cell differentiation. PROTAC FLT3/CDKs degrader-1 inhibits leukemia cell proliferation. PROTAC FLT3/CDKs degrader-1 can be used for the research of acute myeloid leukemia .
Cat. No.: HY-130712
CAS No.: 1692613-62-9
Target:
Research Areas:
NH2-C2-amido-C2-Boc is a PROTAC linker, which refers to the alkyl/ether composition. NH2-C5-NH-Boc can be used in the synthesis of a series of PROTACs, such as the PROTAC CDK2/9 Degrader-1 (HY-130709) .
Cat. No.: HY-178084
CAS No.: 2488075-62-1
Research Areas:
CDK2 ligand-3 is a target protein ligand for PROTACs. CDK2 ligand-3 can be used to synthesize the PROTAC CDK2 Degrader-1 (HY-168057) .
Cat. No.: HY-W1047040
CAS No.: 1211585-07-7
Research Areas:
CDK2/4 ligand 1 is a ligand for target protein for PROTACs, which targets CDK2/4. CDK2/4 ligand 1 can be used for synthesis of PROTAC CDK2/4 Degrader-1 (HY-179688) .
Cat. No.: HY-130980
CAS No.: 2183502-77-2
Research Areas:
N-Desmethyl FN-1501 (Compound 2) is a CDK2/9 ligand that can be used to synthesize PROTACs, such as PROTAC CDK2/9 Degrader-1 (HY-130709) .
Cat. No.: HY-185121
CAS No.: 2541626-49-5
PROTAC CDK2/4/6 Degrader-2 is a CDK2/4/6 PROTAC degrader. PROTAC CDK2/4/6 Degrader-2. PROTAC CDK2/4/6 Degrader-2 can be converted into the prodrug PROTAC CDK2/4/6 Degrader-1 (HY-171826) through a one-step reaction with chloromethyl pivalate. PROTAC CDK2/4/6 Degrader-2 degrades CDK2/4/6 and their complex in malignant melanomas cells. PROTAC CDK2/4/6 Degrader-2 induces cell cycle arrest and cell apoptosis in various cancer cells, in particular for melanomas. PROTAC CDK2/4/6 Degrader-2 can be used for malignant melanomas research .
Cat. No.: HY-W883326
CAS No.: 2913408-82-7
Target:
Research Areas:
CRBN ligand-902 is a CRBN E3 ligase ligand that can be used for synthesis of PROTAC CDK2/4 Degrader-1 (HY-179688) .
Cat. No.: HY-178085
CAS No.: 3024973-03-0
Target:
Research Areas:
E3 ligase Ligand 73 is an E3 ligase ligand used for PROTACs. E3 ligase Ligand 73 can be used to synthesize the PROTAC CDK2 Degrader-1 (HY-168057) .
Cat. No.: HY-181134
CAS No.: 2715104-46-2
PROTAC HMGCR Degrader-2 is a HMGCR PROTAC degrader with an IC50 value of 0.25 μM. PROTAC degrades HMGCR-2 in Insig-silenced HepG2 cells with a DC50 of 0.12 μM. PROTAC HMGCR Degrader-2 takes PROTAC HMGCR Degrader-1 (HY-171823) as the oral prodrug. PROTAC HMGCR Degrader-2 degrades HMGCR by the VHL-dependent ubiquitin-proteasome system and reduces cellular cholesterol in HepG2 cells. PROTAC CDK2/4/6 Degrader-2 can be used for hyperlipidemia research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
